Dr. See Hyoung Park
My Social Links

Dr. See Hyoung Park

Senior Scientist
Seoul National University Bundang Hospital, Korea

Highest Degree
Ph.D. in Comparative Pathology from University of California, USA

Share this Profile


See-Hyoung Park currently works as principle investigator in Seoul National University, Graduate School of Convergence Science and Technology, Korea (South). He received his Ph.D. degree in 2009 from the Graduate Group of Comparative Pathology (GGCP) at University of California in Davis, where he received the Block Grant from GGCP that covered part of his tuition and fees. His prior work experience includes senior scientific researcher at Mogam Biotechnology Research Institute, one of the renowned Biotechnology Institutes and Dr. Mickey Hus laboratory in the Division of Gynecologic Oncology at Stanford University Medical Center and Stanford Cancer Institute as a Postdoctoral scholar. Dr. Park demonstrated the highest degree of enthusiasm in pursuing anti-cancer drug discovery using chemical genomics since he joined Stanford University, and he has identified a number of novel anticancer compounds based on his innovative drug-discovery strategies.

Area of Interest:

Biomedical Sciences
Cancer Biology
Chemical Genomics
Drug Delivery System
Natural Compounds

Research Publications in Numbers


Selected Publications

  1. Bae, J.S., S.H. Park, K.M. Kim, K.S. Kwon and C.Y. Kim et al., 2015. CK2α phosphorylates DBC1 and involves in the progression of gastric carcinoma and predicts poor survival of gastric carcinoma patients. Int. J. Cancer, 136: 797-809.
    PubMed  |  
  2. Park, S.H., J.H. Lee, J.S. Berek and M.C.T. Hu, 2014. Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53. Int. J. Oncol., 45: 1691-1698.
    PubMed  |  
  3. Liu, R., H.I. Wettersten, S.H. Park and R.H. Weiss, 2013. Small-molecule inhibitors of p21 as novel therapeutics for chemotherapy-resistant kidney cancer. Future Med. Chem., 5: 991-994.
    PubMed  |  
  4. Chung, Y.M., S.H. Park, W.B. Tsai, S.Y. Wang and M.A. Ikeda et al., 2012. FOXO3 signaling links ATM to the p53 apoptotic pathway following DNA damage. Nature Commun., Vol. 3. 10.1038/ncomms200.
    CrossRef  |  PubMed  |  
  5. Tsai, W.B., Y.M. Chung, Y. Zou, S.H. Park and Z. Xu et al., 2010. Inhibition of FOXO3 tumor suppressor function by beta-TrCP1 through ubiquitin-mediated degradation in a tumor mouse model. PLoS One, Vol. 5. .
  6. Yao, N., W. Xiao, X. Wang, J. Marik, S.H. Park, Y. Takada and K.S. Lam, 2009. Discovery of targeting ligands for breast cancer cells using the one-bead one-compound combinatorial method. J. Med. Chem., 52: 126-133.
    PubMed  |  
  7. Park, J.Y., S.H. Park and R.H. Weiss, 2009. Disparate effects of roscovitine on renal tubular epithelial cell apoptosis and senescence: Implications for ADPKD. Am. J. Nephrol., 29: 509-515.
    PubMed  |  
  8. Liu, J.Y., S.H. Park, C. Morisseau, S.H. Hwang, B.D. Hammock and R.H. Weiss, 2009. Sorafenib has soluble epoxide hydrolase inhibitory activity which contributes to its effect profile in vivo. Mol. Cancer Therap., 8: 2193-2203.
    CrossRef  |  PubMed  |  
  9. Park, S.H., X. Wang, R. Liu, K.S. Lam and R.H. Weiss, 2008. High throughput combinatorial screening of small molecules to identify attenuator of p21 as potential novel therapy of renal cell carcinoma. Cancer Biol. Ther., 7: 2015-2022.
    PubMed  |  
  10. Park, S.H., J.Y. Park and R.H. Weiss, 2008. Antisense attenuation of p21 sensitizes kidney cancer to apoptosis in response to conventional DNA-damaging chemotherapy associated with enhancement of phospho-p53. J. Urol., 180: 352-360.
    PubMed  |  
  11. Park, S.H., H.S. Oh, M.A. Kang, H. Cho, J.B. Prasad, J. Won and K.H. Lee, 2007. Structure activity relationship of the series of non-peptide small antagonists for p56lck sh2 domain. Bioorg. Med. Chem., 15: 3938-3950.
    PubMed  |  
  12. Park, S.H., M.A. Kang, H.S. Shim, H. Cho, J. Won and K.H. Lee, 2006. Development of novel small chemical inhibitors for Lck SH2 domain with in vitro T-cell inhibitory activity. Bull. Korean Chem. Soc., 27: 1353-1358.
  13. Kang, K.Y., J.H. Park, I.H. Lim, S.G. Kim and S.H. Park et al., 2006. Crystallization of antiangiogenic kringle V derived from human apolipoprotein A: Crystallization applied to purification and formulation. Biosci. Biotechnol. Biochem., 70: 916-925.
    PubMed  |  
  14. Woo, S.H., S.H. Park, H.K. Lim and K.H. Jung, 2005. Extended operation of a pressurized 75-L bioreactor for shLkn-1 production by Pichia pastoris using dissolved oxygen profile control. J. Microbiol. Biotechnol., 32: 478-480.
    PubMed  |  
  15. Lee, K.H. and S.H. Park, 2004. The relationship between the pY+3 amino acid in the phosphopeptide ligands and the binding affinity for various SH2 domains. Protein Peptide Lett., 11: 527-532.
    PubMed  |  
  16. Won, J., Y.G. Hur, E.M. Hur, S.H. Park and M.A. Kang et al., 2003. Rosmarinic acid inhibits TCR-induced T cell activation and proliferation in an Lck-dependent manner. Eur. J. Immunol., 33: 870-879.
    CrossRef  |  Direct Link  |  
  17. Park, S.H., S.H. Kang, S.H. Lim, H.S. Oh and K.H. Lee, 2003. Design and synthesis of small chemical inhibitors containing different scaffolds for lck SH2 domain. Bioorg. Med. Chem. Lett., 13: 3455-3459.
    Direct Link  |  
  18. Kang, S.H., S.H. Park, H.S. Shim and K.H. Lee, 2003. Non-phosphopeptide inhibitor for Lck SH2 domain: Solid-phase synthesis and structure activity relationship of rosmarinic acid analogs. Bull. Korean Chem. Soc., 24: 664-666.
  19. Park, S.H., J. Won and K.H. Lee, 2002. Design and characterization of non-phosphopeptide inhibitors for src family SH2 domains. Bioorg. Med. Chem. Lett., 12: 2711-2714.
    PubMed  |  
  20. Park, S.H., S.W. Yun, J.M. Park, S.H. Ok, J.H. Yu and D.H. Bai , 2000. Studies on xanthine oxidase inhibitor produced from Aspergilus SP. F184. Korean J. Microbiol. Biotechnol., 28: 92-96.